D. E. Shaw & Co., Inc. Syros Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.69 - $1.21 $84,048 - $147,388	-121,809 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.02 - $3.8 $124,245 - $462,874	121,809 New	121,809 $145,000
Q2 2021 Aug 16, 2021	SELL	$5.01 - $7.48 $188,776 - $281,846	-37,680 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$7.19 - $14.95 $1.41 Million - $2.93 Million	-196,007 Reduced 83.88%	37,680 $282,000
Q4 2020 Feb 16, 2021	BUY	$6.66 - $14.66 $283,116 - $623,196	42,510 Added 22.24%	233,687 $2.54 Million
Q3 2020 Nov 16, 2020	SELL	$8.69 - $14.47 $358,479 - $596,916	-41,252 Reduced 17.75%	191,177 $1.69 Million
Q2 2020 Aug 14, 2020	BUY	$5.21 - $11.03 $769,053 - $1.63 Million	147,611 Added 174.03%	232,429 $2.48 Million
Q1 2020 May 15, 2020	SELL	$4.46 - $9.2 $277,675 - $572,782	-62,259 Reduced 42.33%	84,818 $503,000
Q4 2019 Feb 14, 2020	BUY	$4.52 - $10.1 $335,108 - $748,803	74,139 Added 101.65%	147,077 $1.02 Million
Q3 2019 Nov 14, 2019	SELL	$7.14 - $11.65 $152,710 - $249,170	-21,388 Reduced 22.67%	72,938 $757,000
Q2 2019 Aug 14, 2019	SELL	$5.5 - $9.75 $101,002 - $179,049	-18,364 Reduced 16.3%	94,326 $873,000
Q1 2019 May 15, 2019	BUY	$5.51 - $9.59 $131,182 - $228,318	23,808 Added 26.79%	112,690 $1.03 Million
Q4 2018 Feb 14, 2019	BUY	$5.55 - $11.34 $436,180 - $891,221	78,591 Added 763.69%	88,882 $496,000
Q3 2018 Nov 14, 2018	BUY	$9.74 - $12.92 $100,234 - $132,959	10,291 New	10,291 $123,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $4.25M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.